Navigation Links
Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
Date:12/1/2009

statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the operation of the global collaboration with Bayer Schering Pharma, the efficacy, safety and intended utilization of our product candidates, including the BiTE antibody that is the subject of the agreement with Bayer Schering Pharma, the mode of action of BiTE antibodies, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and the future payment of milestone and royalty payments by Bayer Schering Pharma. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborat
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
2. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
3. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health, First-Ever Leading Calcium Supplement to Help Support Bone AND Heart Health
4. Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
5. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
6. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
7. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... LOS ANGELES , Oct. 29, 2014 /PRNewswire/ ... pharmaceutical company devoted to bringing new products to ... 2015. ViaDerma has developed an innovative, ... for rapid mass transfer of pharmaceutical active ingredients ... to provide immediate localized therapy. The transdermal delivery ...
(Date:10/30/2014)... Oct. 30, 2014 Today Eli Lilly and ... its long-standing technology transfer program to increase the global ... 2003, the effort included Lilly donating manufacturing technology and ... China , India , ... Africa – all MDR-TB ,hot spots., It ...
(Date:10/27/2014)... , Oct. 27, 2014  Demonstrations by ... devices are being featured this week in ... Scientific Assembly where more than 7,000 emergency physicians ... and participating in educational courses. These ... drop of true-to-life emergency department environments, including three ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
(Date:10/30/2014)... 30, 2014 Victory Healthcare, a ... 2014 third quarter infection rates and patient satisfaction ... rates of only two percent or less, and ... exceeding 98 percent. , “We are delighted with ... rising satisfaction scores,” said Robert Helms, chairman and ...
(Date:10/30/2014)... who used stem cells to create miniature human stomachs ... new way to learn more about the development and ... pluripotent stem cells -- which can become any type ... functional miniature stomachs, to study infection by H. ... stomach cancer. The miniature stomachs offer many research ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Many U.S. ... campus, even though tanning increases the risk for ... among young adults, particularly white women, so colleges ... health, the researchers said. "Public health efforts ... population awareness of the harms that indoor tanning ...
(Date:10/30/2014)... -- A new vaccine that could help prevent some ... the U.S. Food and Drug Administration on Wednesday. ... of 10 and 25 from invasive meningococcal disease caused ... The bacteria can infect the bloodstream (sepsis) and the ... is a leading cause of bacterial meningitis, and infection ...
(Date:10/29/2014)... development of minimally and even non-invasive technologies is increasing ... instance, to carry out a range of operative procedures ... leaving only tiny scars as a result. Similar opportunities ... agents to patients – instead of using injections or ... possible to supply them via a plaster which continuously, ...
Breaking Medicine News(10 mins):Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Gentle caffeine boost for premature babies 2
... . , The PhD, defended by Ana ... Country, proposes a series of recommendations that contribute to ... treat terminal cancer patients. , Autonomy is the capacity ... knowledge about the causes of the illness, sufficient information ...
... Shared Health, Inc.,provider of secure health information ... Tennessee to provide its electronic health record,solutions ... health information,network called the Tennessee Information Network ... partnership with the State of Tennessee began ...
... The Providence Service,Corporation (Nasdaq: PRSC ) today announced ... fourth quarter and year ended December 31, 2007,on Wednesday, ... will hold a conference call at 11:00 a.m. EDT ... March 13, 2008 to discuss its,financial results and corporate ...
... Bowl champ O.J. Brigance,who recently confirmed a diagnosis ... The Robert Packard Center for ALS Research at ... the Center to fund,research to find a cure ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080303/NEM042 ), The ...
... Faculty of 1000 Medicine, researchers look at the way ... used by physicians in Quebec. , The authors ... that general practitioners diagnosed 79% of the 10,001 rheumatoid ... a rheumatologist. Half of these patients were seen in ...
... study has found that elevated liver enzymes discovered ... future mortality. The findings are in the March ... Wiley & Sons on behalf of the American ... The article is also available online at Wiley ...
Cached Medicine News:Health News:Factors that enhance autonomy of cancer patients 2Health News:Factors that enhance autonomy of cancer patients 3Health News:Shared Health Partners With State of Tennessee to Provide Electronic Health Information for Statewide Health Information Network 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 3Health News:O.J. Brigance Named Honorary Chair of May 3 Race to Cure ALS, Confirms His Diagnosis by The Robert Packard Center for ALS Research at Johns Hopkins 2Health News:Elevated liver enzymes associated with higher future mortality 2
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
... fit for all astigmatic patients. Ideal ... who require excellent visual acuity and ... of disposable lenses; astigmatic spectacle wearers ... lenses; and spherically masked astigmatic patients ...
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
... Vitrasert implant is a device ... with Aids-related Cytomegalovirus (CMV) Retinitis. This ... CMV when compared with conventional intravenous ... embedded in a polymer-based system that ...
Medicine Products: